panitumumab
Amgen
['radio']
an open-label, noninferiority phase iii rct of weekly versus three weekly cisplatin and radical radiotherapy in lahnscc (concert trial) | #asco22
complement to jcog1008 in the definitive setting 
@KP_LAMC Radiation Oncology Residency APD ?? | @KPMedSchool Assistant Professor and Radiation Oncology Clerkship Director | @UCBerkeley GO BEARS! ??